{"analyses":[{"ciLowerLimit":"0.476","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.519","estimateComment":"The hazard ratio was estimated using a stratified Cox proportional hazards model.","groupIds":["OG000","OG001"],"nonInferiorityComment":"Only primary and key secondary endpoints were formally tested; this endpoint was not formally tested.","nonInferiorityType":"SUPERIORITY","pValue":"0.5837","paramType":"Hazard Ratio (HR)","paramValue":"0.850","statisticalMethod":"stratified Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"96.7","upperLimit":"99.5","value":"98.7"},{"groupId":"OG001","lowerLimit":"93.8","upperLimit":"98.1","value":"96.5"}]}],"title":"6 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"93.4","upperLimit":"98.1","value":"96.4"},{"groupId":"OG001","lowerLimit":"91.2","upperLimit":"96.5","value":"94.4"}]}],"title":"2 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"87.7","upperLimit":"95.1","value":"92.2"},{"groupId":"OG001","lowerLimit":"87.4","upperLimit":"94.5","value":"91.7"}]}],"title":"18 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"84.4","upperLimit":"93.7","value":"90.1"},{"groupId":"OG001","lowerLimit":"81.1","upperLimit":"92.8","value":"88.3"}]}],"title":"2 years"}],"denoms":[{"counts":[{"groupId":"OG000","value":"326"},{"groupId":"OG001","value":"328"}],"units":"Participants"}],"description":"Overall survival was defined as the time from randomization until death from any cause. Kaplan-Meier estimates indicate the percent probability of a participant being alive at the indicated time after treatment start.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with FL and MZL were randomized to receive tafasitamab 12 mg/kg IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.","id":"OG000","title":"FL and MZL: Tafasitamab + Rituximab + Lenalidomide"},{"description":"Participants with FL and MZL were randomized to receive placebo 0.9% saline solution IV, administered on Days 1, 8, 15, and 22 of Cycles 1 to 3 and on Days 1 and 15 of Cycles 4 to 12. Participants also received oral lenalidomide (including generics) 20 mg QD, administered at approximately the same time every day on Days 1 to 21 of Cycles 1 to 12, and rituximab (including biosimilars) 375 mg/m\\^2 IV, administered on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. A treatment cycle was defined as 28 calendar days.","id":"OG001","title":"FL and MZL: Placebo + Rituximab + Lenalidomide"}],"paramType":"NUMBER","populationDescription":"Overall Full Analysis Set. As pre-specified in the Statistical Analysis Plan, the MZL population was considered as a subpopulation of interest, not a main analysis population. The FL and MZL populations were combined for analysis into the Overall population, which was a main analysis population. Censored participants were included in the analysis. The number of participants analyzed for the Kaplan-Meier estimate at each time point refers to the total number of participants in the analysis set.","reportingStatus":"POSTED","timeFrame":"up to 2 years","title":"Overall Population: Kaplan-Meier Estimates of Overall Survival","type":"SECONDARY","unitOfMeasure":"percent probability"}